Internal Medicine
AGH General Surgery Residency Program

AGH General Residency Program Home
About the Program
About the Region
Why AGH?

Find Out More...
Surgery Residents
Our Graduates
Faculty
Director's Statement
Message from the President
Residency Program Goals and Objectives
Core Curriculum
Surgical Subspecialties
Conferences
Stipends and Benefits
Research
Resident Resources
Application Information
Appointment Contract
Hotel Information
Links to Pittsburgh Information
Contact Information

Colon and Rectal Surgery Fellowship

Bariatric Surgery Fellowship

Susan G. Komen Interdisciplinary Breast Fellowship

Vascular Surgery Fellowship Program



Accurate Axillary Nodal Staging Can Be Achieved Following Neoadjuvant Therapy For Locally Advanced Breast Cancer

Patel, NA, Piper, G, Patel, JA and Julian, TB

Lymph node status remains the most important prognostic indicator for breast cancer. Recent reports have established that the probability of accurately assessing lymph node status is proportionate with the number of nodes dissected. The accuracy of axillary staging following neoadjuvant chemotherapy has been raised as a technical concern due to limited node retrieval. The present study attempts to evaluate the ability to perform sentinel node biopsy (SNB) and formal axillary dissection (AND) following neoadjuvant chemotherapy and to compare these results with non-neoadjuvant patients.

One hundred and sixteen consecutive patients undergoing SNB with simultaneous AND were retrospectively reviewed. Forty two of these patients were treated with neoadjuvant chemotherapy prior to AND. Overall success rate in performing SNB in the neoadjuvant group was 95% and only 1 false negative (2%) has been noted to date. The overall SNB success rate in the non-neoadjuvant group was also 95% with a false negative rate of 2%. Following AND in each group a mean of 21 nodes were retrieved in the neoadjuvant group and 17.9 nodes in the non neoadjuvant group (p = 0.018). In the neoadjuvant group, there were 19 node positive patients (42%) and 21 patients (28%) in the non-neoadjuvant group (p=0.16). The mean number of positive nodes per patient was also similar between the two groups (2.9 in the neoadjuvant group vs 1.67 in the non-neoadjuvant group, p=0.10).

Following neoadjuvant therapy, accurate evaluation of the axilla is feasible. In this study, the mean number of nodes is significantly different in favor of the neoadjuvant group, but there is no significant difference in the number of node positive patients identified or in the mean number of positive nodes identified per patient. SNB is technically feasible with accuracy similar to that seen in patients with no history of neoadjuvant therapy. Neoadjuvant chemotherapy extends the use of breast conserving therapy without sacrificing the ability to accurately stage the axilla either by use of standard axillary dissection or SNB.



> Back



AGH General Surgery Residency Program Home | Disclaimer | Contact Webmaster

© West Penn Allegheny Health System. All rights reserved.